Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study

Lea Fayad, Atif Adam, Michael A Schweitzer, Lawrence J Cheskin, Tokunbo Ajayi, Margo Dunlap, Dilhana Badurdeen, Christine Hill, Neethi Paranji, Sepehr Lalezari, Anthony N Kalloo, Mouen Khashab, Vivek Kumbhari

Research output: Contribution to journalArticle

Abstract

Background and Aims: Endoscopic sleeve gastroplasty (ESG) reduces the gastric lumen to a size comparable with that of laparoscopic sleeve gastrectomy (LSG). However, there is a paucity of research comparing outcomes between the 2 procedures. Our study compared the 6-month weight loss outcomes and adverse events of ESG with LSG in a case-matched cohort. Methods: We retrospectively reviewed prospectively collected data for patients undergoing ESG or LSG at a single academic center. Weight was recorded at 1 and 6 months postprocedure, and percent total body weight loss (%TBWL) was calculated. Adverse events and new-onset Gastroesophageal Reflux Disease (GERD) were also recorded. Results: A total of 54 ESG patients were matched with 83 LSG patients by age, sex, and body mass index. The proportion of patients with GERD at baseline was similar in the 2 groups (16.7% in ESG group vs 25.3% in LSG group, P =.27). At the 6-month follow-up, %TBWL (compared with baseline) was significantly lower in the ESG group compared with the LSG group (17.1% ± 6.5% vs 23.6% ± 7.6%, P <.01). ESG patients had significantly lower rates of adverse events compared with LSG patients (5.2% vs 16.9%, P <.05). New-onset GERD was also significantly lower in the ESG group compared with the LSG group (1.9% vs 14.5%, P <.05). Conclusions: ESG, a minimally invasive same-day procedure, achieved less weight loss at 6 months than LSG, with the caveat that LSG caused more adverse events and new-onset GERD than ESG.

Original languageEnglish (US)
JournalGastrointestinal Endoscopy
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Gastroplasty
Gastrectomy
Gastroesophageal Reflux
Weight Loss
Stomach
Body Mass Index
Body Weight
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Cite this

Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy : a case-matched study. / Fayad, Lea; Adam, Atif; Schweitzer, Michael A; Cheskin, Lawrence J; Ajayi, Tokunbo; Dunlap, Margo; Badurdeen, Dilhana; Hill, Christine; Paranji, Neethi; Lalezari, Sepehr; Kalloo, Anthony N; Khashab, Mouen; Kumbhari, Vivek.

In: Gastrointestinal Endoscopy, 01.01.2018.

Research output: Contribution to journalArticle

@article{fff4ad31bc0147258bdd36b75c44e607,
title = "Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study",
abstract = "Background and Aims: Endoscopic sleeve gastroplasty (ESG) reduces the gastric lumen to a size comparable with that of laparoscopic sleeve gastrectomy (LSG). However, there is a paucity of research comparing outcomes between the 2 procedures. Our study compared the 6-month weight loss outcomes and adverse events of ESG with LSG in a case-matched cohort. Methods: We retrospectively reviewed prospectively collected data for patients undergoing ESG or LSG at a single academic center. Weight was recorded at 1 and 6 months postprocedure, and percent total body weight loss ({\%}TBWL) was calculated. Adverse events and new-onset Gastroesophageal Reflux Disease (GERD) were also recorded. Results: A total of 54 ESG patients were matched with 83 LSG patients by age, sex, and body mass index. The proportion of patients with GERD at baseline was similar in the 2 groups (16.7{\%} in ESG group vs 25.3{\%} in LSG group, P =.27). At the 6-month follow-up, {\%}TBWL (compared with baseline) was significantly lower in the ESG group compared with the LSG group (17.1{\%} ± 6.5{\%} vs 23.6{\%} ± 7.6{\%}, P <.01). ESG patients had significantly lower rates of adverse events compared with LSG patients (5.2{\%} vs 16.9{\%}, P <.05). New-onset GERD was also significantly lower in the ESG group compared with the LSG group (1.9{\%} vs 14.5{\%}, P <.05). Conclusions: ESG, a minimally invasive same-day procedure, achieved less weight loss at 6 months than LSG, with the caveat that LSG caused more adverse events and new-onset GERD than ESG.",
author = "Lea Fayad and Atif Adam and Schweitzer, {Michael A} and Cheskin, {Lawrence J} and Tokunbo Ajayi and Margo Dunlap and Dilhana Badurdeen and Christine Hill and Neethi Paranji and Sepehr Lalezari and Kalloo, {Anthony N} and Mouen Khashab and Vivek Kumbhari",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.gie.2018.08.030",
language = "English (US)",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy

T2 - a case-matched study

AU - Fayad, Lea

AU - Adam, Atif

AU - Schweitzer, Michael A

AU - Cheskin, Lawrence J

AU - Ajayi, Tokunbo

AU - Dunlap, Margo

AU - Badurdeen, Dilhana

AU - Hill, Christine

AU - Paranji, Neethi

AU - Lalezari, Sepehr

AU - Kalloo, Anthony N

AU - Khashab, Mouen

AU - Kumbhari, Vivek

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background and Aims: Endoscopic sleeve gastroplasty (ESG) reduces the gastric lumen to a size comparable with that of laparoscopic sleeve gastrectomy (LSG). However, there is a paucity of research comparing outcomes between the 2 procedures. Our study compared the 6-month weight loss outcomes and adverse events of ESG with LSG in a case-matched cohort. Methods: We retrospectively reviewed prospectively collected data for patients undergoing ESG or LSG at a single academic center. Weight was recorded at 1 and 6 months postprocedure, and percent total body weight loss (%TBWL) was calculated. Adverse events and new-onset Gastroesophageal Reflux Disease (GERD) were also recorded. Results: A total of 54 ESG patients were matched with 83 LSG patients by age, sex, and body mass index. The proportion of patients with GERD at baseline was similar in the 2 groups (16.7% in ESG group vs 25.3% in LSG group, P =.27). At the 6-month follow-up, %TBWL (compared with baseline) was significantly lower in the ESG group compared with the LSG group (17.1% ± 6.5% vs 23.6% ± 7.6%, P <.01). ESG patients had significantly lower rates of adverse events compared with LSG patients (5.2% vs 16.9%, P <.05). New-onset GERD was also significantly lower in the ESG group compared with the LSG group (1.9% vs 14.5%, P <.05). Conclusions: ESG, a minimally invasive same-day procedure, achieved less weight loss at 6 months than LSG, with the caveat that LSG caused more adverse events and new-onset GERD than ESG.

AB - Background and Aims: Endoscopic sleeve gastroplasty (ESG) reduces the gastric lumen to a size comparable with that of laparoscopic sleeve gastrectomy (LSG). However, there is a paucity of research comparing outcomes between the 2 procedures. Our study compared the 6-month weight loss outcomes and adverse events of ESG with LSG in a case-matched cohort. Methods: We retrospectively reviewed prospectively collected data for patients undergoing ESG or LSG at a single academic center. Weight was recorded at 1 and 6 months postprocedure, and percent total body weight loss (%TBWL) was calculated. Adverse events and new-onset Gastroesophageal Reflux Disease (GERD) were also recorded. Results: A total of 54 ESG patients were matched with 83 LSG patients by age, sex, and body mass index. The proportion of patients with GERD at baseline was similar in the 2 groups (16.7% in ESG group vs 25.3% in LSG group, P =.27). At the 6-month follow-up, %TBWL (compared with baseline) was significantly lower in the ESG group compared with the LSG group (17.1% ± 6.5% vs 23.6% ± 7.6%, P <.01). ESG patients had significantly lower rates of adverse events compared with LSG patients (5.2% vs 16.9%, P <.05). New-onset GERD was also significantly lower in the ESG group compared with the LSG group (1.9% vs 14.5%, P <.05). Conclusions: ESG, a minimally invasive same-day procedure, achieved less weight loss at 6 months than LSG, with the caveat that LSG caused more adverse events and new-onset GERD than ESG.

UR - http://www.scopus.com/inward/record.url?scp=85054681695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054681695&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2018.08.030

DO - 10.1016/j.gie.2018.08.030

M3 - Article

C2 - 30148991

AN - SCOPUS:85054681695

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

ER -